|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
EE05627B1
(et)
*
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US7357928B2
(en)
*
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
|
CN1652820A
(zh)
*
|
2002-04-12 |
2005-08-10 |
梅达雷克斯公司 |
使用ctla－4抗体的治疗方法
|
|
SG2013096847A1
(en)
|
2002-09-06 |
2017-05-30 |
Medarex Llc |
Therapeutic human anti-il-1r1 monoclonal antibody
|
|
US20040197312A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
|
KR101531400B1
(ko)
|
2003-06-27 |
2015-06-26 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
|
|
US7335748B2
(en)
|
2003-07-22 |
2008-02-26 |
Bayer Schering Pharma Aktiengesellschaft |
RG1 antibodies and uses thereof
|
|
JP2007528721A
(ja)
|
2003-08-14 |
2007-10-18 |
ダイアックス コーポレイション |
エンドセリアーゼ−２リガンド
|
|
EP1515505A1
(en)
*
|
2003-09-12 |
2005-03-16 |
Siemens Aktiengesellschaft |
Reachability maintainance of a moving network based on temporary name identifiers
|
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
WO2005074633A2
(en)
*
|
2004-02-03 |
2005-08-18 |
The Regents Of The University Of Michigan |
Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
|
|
RU2346702C2
(ru)
*
|
2004-03-26 |
2009-02-20 |
Пфайзер Продактс Инк. |
Применение антител к ctla-4
|
|
US7785591B2
(en)
|
2004-10-14 |
2010-08-31 |
Morphosys Ag |
Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
|
|
WO2006048749A1
(en)
*
|
2004-11-04 |
2006-05-11 |
Pfizer Products Inc. |
Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
|
|
BRPI0608815B1
(pt)
|
2005-03-08 |
2021-10-13 |
Pfizer Products Inc |
Composições de anticorpo anti-ctla-4
|
|
WO2006101691A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
|
|
MX2007011767A
(es)
*
|
2005-03-23 |
2007-10-18 |
Pfizer Prod Inc |
Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer.
|
|
KR101318469B1
(ko)
*
|
2005-05-09 |
2013-10-23 |
메다렉스, 인코포레이티드 |
예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체,및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와병용한 암 치료 방법
|
|
KR101804078B1
(ko)
|
2005-06-08 |
2017-12-01 |
다나-파버 캔서 인스티튜트 인크. |
예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
|
|
WO2007008463A2
(en)
*
|
2005-07-07 |
2007-01-18 |
Coley Pharmaceutical Group, Inc. |
Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
|
|
EP1954311A4
(en)
|
2005-12-07 |
2009-12-23 |
Medarex Inc |
CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
|
|
WO2007113648A2
(en)
*
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
WO2009016449A1
(en)
*
|
2007-07-27 |
2009-02-05 |
Pfizer Limited |
Antibody purification process by precipitation
|
|
RU2499599C2
(ru)
|
2007-09-28 |
2013-11-27 |
Интрексон Корпорейшн |
Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение
|
|
RU2373836C2
(ru)
*
|
2007-12-18 |
2009-11-27 |
Федеральное государственное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова Федерального агентства по высокотехнологичной медицинской помощи" |
Способ оптимизации лечебной тактики при лимфоме ходжкина у детей и подростков
|
|
AU2009204194A1
(en)
*
|
2008-01-08 |
2009-07-16 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
KR101733255B1
(ko)
*
|
2009-07-20 |
2017-05-08 |
브리스톨-마이어스 스큅 컴퍼니 |
증식성 질환의 상승작용적 치료를 위한 항ｃｔｌａ４ 항체와 다양한 치료 요법의 조합
|
|
RU2421217C2
(ru)
*
|
2009-09-03 |
2011-06-20 |
Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) |
Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
|
|
EP3536708A1
(en)
|
2011-04-19 |
2019-09-11 |
Pfizer Inc |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
|
DK3446714T3
(da)
|
2011-06-02 |
2021-05-10 |
Univ Louisville Res Found Inc |
Anti-nucleolinmiddel-konjugerede nanopartikler
|
|
EA201400996A1
(ru)
|
2012-03-13 |
2015-03-31 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия для лечения рака яичника
|
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
|
PT2887959T
(pt)
*
|
2012-08-23 |
2019-02-01 |
Seattle Genetics Inc |
Conjugados anticorpo-fármaco (adc) que se ligam a proteínas 158p1d7
|
|
HRP20190574T1
(hr)
*
|
2012-12-03 |
2019-05-17 |
Bristol-Myers Squibb Company |
Poboljšanje anti-kancerogene aktivnosti imunomodulatornih fc fuzijskih proteina
|
|
EP3030262B1
(en)
|
2013-08-08 |
2019-10-09 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
BR112016002614B8
(pt)
|
2013-08-08 |
2023-11-07 |
Hopitaux Paris Assist Publique |
Imunocitoquina e composição farmacêutica
|
|
CN105636986B
(zh)
*
|
2013-10-18 |
2020-05-12 |
瑞泽恩制药公司 |
包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
|
|
CA2944456C
(en)
*
|
2014-03-31 |
2023-10-31 |
The Johns Hopkins University |
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
|
|
KR20170002403A
(ko)
*
|
2014-05-01 |
2017-01-06 |
가부시키가이샤 아네로파마·사이엔스 |
이종 폴리펩티드 발현 카세트
|
|
DK3148579T3
(da)
|
2014-05-28 |
2021-03-08 |
Agenus Inc |
Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
DK3186281T3
(da)
|
2014-08-28 |
2019-06-11 |
Halozyme Inc |
Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor
|
|
EP3204516B1
(en)
|
2014-10-06 |
2023-04-26 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
CN108064282A
(zh)
|
2014-10-14 |
2018-05-22 |
哈洛齐梅公司 |
腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
|
|
EP3240801B1
(en)
|
2014-12-31 |
2021-01-20 |
Checkmate Pharmaceuticals, Inc. |
Combination tumor immunotherapy
|
|
CN114014930A
(zh)
*
|
2015-02-13 |
2022-02-08 |
索伦托药业有限公司 |
结合ctla4的抗体治疗剂
|
|
WO2016179394A1
(en)
|
2015-05-05 |
2016-11-10 |
Malik Mohammad Tariq |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
|
CN107849144B
(zh)
*
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
|
CN114853891A
(zh)
*
|
2015-07-22 |
2022-08-05 |
索伦托药业有限公司 |
与lag3结合的抗体治疗剂
|
|
US11419934B2
(en)
|
2015-08-18 |
2022-08-23 |
Oncotelic Therapeutics, Inc. |
Use of VDAS to enhance immunomodulating therapies against tumors
|
|
TW202134282A
(zh)
|
2015-12-02 |
2021-09-16 |
美商艾吉納斯公司 |
抗體和使用彼之方法
|
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
|
US11760803B2
(en)
|
2016-03-24 |
2023-09-19 |
Takeda Pharmaceutical Company Limited |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
|
EA039322B1
(ru)
*
|
2016-04-15 |
2022-01-13 |
Эйдженус Инк. |
Антитела против ctla-4 и способы их применения
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
WO2018037595A1
(ja)
*
|
2016-08-26 |
2018-03-01 |
哲治 奥野 |
微小血管血流低減剤およびその利用
|
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
|
EP3551660B1
(en)
*
|
2016-12-07 |
2023-09-13 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
CN111699195A
(zh)
|
2018-02-02 |
2020-09-22 |
肿瘤免疫股份有限公司 |
具有改善的免疫治疗效果但减轻的不良作用的突变体抗ctla-4抗体
|
|
US12246031B2
(en)
|
2018-02-13 |
2025-03-11 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
US20230167177A1
(en)
*
|
2018-03-19 |
2023-06-01 |
WuXi Biologics Ireland Limited |
Novel anti-ctla-4 antibody polypeptide
|
|
IL319506A
(en)
|
2018-04-09 |
2025-05-01 |
Checkmate Pharmaceuticals Inc |
Packaging of oligonucleotides in virus-like particles
|
|
CA3106143A1
(en)
|
2018-07-11 |
2020-01-16 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
CN110092826B
(zh)
*
|
2019-02-28 |
2022-04-15 |
天津大学 |
CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
|
|
WO2021238932A1
(zh)
*
|
2020-05-26 |
2021-12-02 |
百奥泰生物制药股份有限公司 |
多特异性抗体及其应用
|
|
AU2021304826A1
(en)
|
2020-07-10 |
2023-02-02 |
The Regents Of The University Of Michigan |
GAS41 inhibitors and methods of use thereof
|
|
WO2022086852A2
(en)
|
2020-10-19 |
2022-04-28 |
Dana-Farber Cancer Institute, Inc. |
Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
|
|
US20240424090A1
(en)
|
2021-04-20 |
2024-12-26 |
Institut Curie |
Compositions and methods for use in immunotherapy
|